Davita - Dublin is a medicare approved dialysis facility center in Dublin, Ohio and it has 12 dialysis stations. It is located in Franklin county at 6770 Perimeter Drive, Dublin, OH, 43016. You can reach out to the office of Davita - Dublin at (614) 798-8359. This dialysis clinic is managed and/or owned by Davita. Davita - Dublin has the following ownership type - Profit. It was first certified by medicare in August, 2008. The medicare id for this facility is 362728 and it accepts patients under medicare ESRD program.
| Name | Davita - Dublin |
|---|---|
| Location | 6770 Perimeter Drive, Dublin, Ohio |
| No. of Dialysis Stations | 12 |
| Medicare ID | 362728 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 6770 Perimeter Drive, Dublin, Ohio, 43016 | |
| (614) 798-8359 | |
News Archive
AMAG Pharmaceuticals, Inc. today announced that new data from two pivotal phase III clinical trials were presented at the American Society of Hematology's (ASH) annual meeting in Atlanta, Georgia.
The National Comprehensive Cancer Network has instituted Categories of Preference for recommendations within the NCCN Clinical Practice Guidelines in Oncology. Initially, Categories of Preference will be published for drugs and biologics recommended within the NCCN Guidelines® for Multiple Myeloma.
According to a new report from State Coverage Initiatives, federal policymakers crafting health reform have yet to address the critical issue of how new or modified federal rules will impact health care delivery systems, insurance regulation, and safety net programs administered by the states.
Four years of follow up including additional patients in the Swedish Coronary angiography and angioplasty registry (SCAAR) does no longer indicate any increased mortality in patients treated with drug eluting stents compared to patients treated with bare metal stents.
› Verified 1 days ago
| NPI Number | 1770768673 |
| Organization Name | Dublin Dialysis |
| Doing Business As | Rna Davita Dialysis Llc |
| Address | 6770 Perimeter Dr Dublin, Ohio, 43016 |
| Phone Number | (614) 798-8359 |
News Archive
AMAG Pharmaceuticals, Inc. today announced that new data from two pivotal phase III clinical trials were presented at the American Society of Hematology's (ASH) annual meeting in Atlanta, Georgia.
The National Comprehensive Cancer Network has instituted Categories of Preference for recommendations within the NCCN Clinical Practice Guidelines in Oncology. Initially, Categories of Preference will be published for drugs and biologics recommended within the NCCN Guidelines® for Multiple Myeloma.
According to a new report from State Coverage Initiatives, federal policymakers crafting health reform have yet to address the critical issue of how new or modified federal rules will impact health care delivery systems, insurance regulation, and safety net programs administered by the states.
Four years of follow up including additional patients in the Swedish Coronary angiography and angioplasty registry (SCAAR) does no longer indicate any increased mortality in patients treated with drug eluting stents compared to patients treated with bare metal stents.
› Verified 1 days ago
| Dialysis patients with Hemoglobin data | 17 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 29 |
News Archive
AMAG Pharmaceuticals, Inc. today announced that new data from two pivotal phase III clinical trials were presented at the American Society of Hematology's (ASH) annual meeting in Atlanta, Georgia.
The National Comprehensive Cancer Network has instituted Categories of Preference for recommendations within the NCCN Clinical Practice Guidelines in Oncology. Initially, Categories of Preference will be published for drugs and biologics recommended within the NCCN Guidelines® for Multiple Myeloma.
According to a new report from State Coverage Initiatives, federal policymakers crafting health reform have yet to address the critical issue of how new or modified federal rules will impact health care delivery systems, insurance regulation, and safety net programs administered by the states.
Four years of follow up including additional patients in the Swedish Coronary angiography and angioplasty registry (SCAAR) does no longer indicate any increased mortality in patients treated with drug eluting stents compared to patients treated with bare metal stents.
› Verified 1 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 41 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 322 |
| Percentage of adult patients getting regular hemodialysis at the center | 96 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
AMAG Pharmaceuticals, Inc. today announced that new data from two pivotal phase III clinical trials were presented at the American Society of Hematology's (ASH) annual meeting in Atlanta, Georgia.
The National Comprehensive Cancer Network has instituted Categories of Preference for recommendations within the NCCN Clinical Practice Guidelines in Oncology. Initially, Categories of Preference will be published for drugs and biologics recommended within the NCCN Guidelines® for Multiple Myeloma.
According to a new report from State Coverage Initiatives, federal policymakers crafting health reform have yet to address the critical issue of how new or modified federal rules will impact health care delivery systems, insurance regulation, and safety net programs administered by the states.
Four years of follow up including additional patients in the Swedish Coronary angiography and angioplasty registry (SCAAR) does no longer indicate any increased mortality in patients treated with drug eluting stents compared to patients treated with bare metal stents.
› Verified 1 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Davita - Dublin with elevated calcium levels.
| Patients with hypercalcemia | 43 |
| Hypercalcemia patient months | 346 |
| Patients with Serumphosphor | 43 |
| Patients with Serumphosphor less than 3.5 mg/dL | 10 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 26 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 26 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 22 |
| Patients with Serumphosphor greater than 7 mg/dL | 17 |
News Archive
AMAG Pharmaceuticals, Inc. today announced that new data from two pivotal phase III clinical trials were presented at the American Society of Hematology's (ASH) annual meeting in Atlanta, Georgia.
The National Comprehensive Cancer Network has instituted Categories of Preference for recommendations within the NCCN Clinical Practice Guidelines in Oncology. Initially, Categories of Preference will be published for drugs and biologics recommended within the NCCN Guidelines® for Multiple Myeloma.
According to a new report from State Coverage Initiatives, federal policymakers crafting health reform have yet to address the critical issue of how new or modified federal rules will impact health care delivery systems, insurance regulation, and safety net programs administered by the states.
Four years of follow up including additional patients in the Swedish Coronary angiography and angioplasty registry (SCAAR) does no longer indicate any increased mortality in patients treated with drug eluting stents compared to patients treated with bare metal stents.
› Verified 1 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 36 |
| Patient months included in arterial venous fistula and catheter summaries | 170 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 54 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 16 |
News Archive
AMAG Pharmaceuticals, Inc. today announced that new data from two pivotal phase III clinical trials were presented at the American Society of Hematology's (ASH) annual meeting in Atlanta, Georgia.
The National Comprehensive Cancer Network has instituted Categories of Preference for recommendations within the NCCN Clinical Practice Guidelines in Oncology. Initially, Categories of Preference will be published for drugs and biologics recommended within the NCCN Guidelines® for Multiple Myeloma.
According to a new report from State Coverage Initiatives, federal policymakers crafting health reform have yet to address the critical issue of how new or modified federal rules will impact health care delivery systems, insurance regulation, and safety net programs administered by the states.
Four years of follow up including additional patients in the Swedish Coronary angiography and angioplasty registry (SCAAR) does no longer indicate any increased mortality in patients treated with drug eluting stents compared to patients treated with bare metal stents.
› Verified 1 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 29 |
| Hospitalization Rate in facility | 279.4 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 510.5 |
| Hospitalization Rate: Lower Confidence Limit | 160.3 |
News Archive
AMAG Pharmaceuticals, Inc. today announced that new data from two pivotal phase III clinical trials were presented at the American Society of Hematology's (ASH) annual meeting in Atlanta, Georgia.
The National Comprehensive Cancer Network has instituted Categories of Preference for recommendations within the NCCN Clinical Practice Guidelines in Oncology. Initially, Categories of Preference will be published for drugs and biologics recommended within the NCCN Guidelines® for Multiple Myeloma.
According to a new report from State Coverage Initiatives, federal policymakers crafting health reform have yet to address the critical issue of how new or modified federal rules will impact health care delivery systems, insurance regulation, and safety net programs administered by the states.
Four years of follow up including additional patients in the Swedish Coronary angiography and angioplasty registry (SCAAR) does no longer indicate any increased mortality in patients treated with drug eluting stents compared to patients treated with bare metal stents.
› Verified 1 days ago
The rate of readmission show you whether patients who were being treated regularly at Davita - Dublin were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 26.4 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 37.9 |
| Readmission Rate: Lower Confidence Limit | 16.8 |
News Archive
AMAG Pharmaceuticals, Inc. today announced that new data from two pivotal phase III clinical trials were presented at the American Society of Hematology's (ASH) annual meeting in Atlanta, Georgia.
The National Comprehensive Cancer Network has instituted Categories of Preference for recommendations within the NCCN Clinical Practice Guidelines in Oncology. Initially, Categories of Preference will be published for drugs and biologics recommended within the NCCN Guidelines® for Multiple Myeloma.
According to a new report from State Coverage Initiatives, federal policymakers crafting health reform have yet to address the critical issue of how new or modified federal rules will impact health care delivery systems, insurance regulation, and safety net programs administered by the states.
Four years of follow up including additional patients in the Swedish Coronary angiography and angioplasty registry (SCAAR) does no longer indicate any increased mortality in patients treated with drug eluting stents compared to patients treated with bare metal stents.
› Verified 1 days ago